Ladang, Aurélie http://orcid.org/0000-0002-5316-3108
Beaudart, Charlotte http://orcid.org/0000-0002-0827-5303
Reginster, Jean-Yves
Al-Daghri, Nasser
Bruyère, Olivier
Burlet, Nansa
Cesari, Matteo
Cherubini, Antonio
da Silva, Mario Coelho
Cooper, Cyrus
Cruz-Jentoft, Alfonso J.
Landi, Francesco
Laslop, Andrea
Maggi, Stefania
Mobasheri, Ali
Ormarsdottir, Sif
Radermecker, Régis
Visser, Marjolein
Yerro, Maria Concepcion Prieto
Rizzoli, René
Cavalier, Etienne
Funding for this research was provided by:
ESCEO
Article History
Received: 14 November 2022
Accepted: 18 December 2022
First Online: 12 January 2023
Change Date: 24 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00223-023-01114-y
Declarations
:
: The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the agencies or organizations with which the authors are affiliated. C. Beaudart reports to be a shareholder of SARQOL SRL, a spin-off of the University of Liege O. Bruyere reports grants or fees from AMGEN, APTISSEN, BIOPHYTIS, IBSA, MEDA, SANOFI, SERVIER, SMB, THERAMEX and UCB outside the submitted work. He also a shareholder of SARQOL SRL, a spin-off of the University of Liege. J-Y. Reginster reports consulting fees or paid advisory boards (IBSA-GENEVRIER, MYLAN, RADIUS HEALTH, PIERRE FABRE, ECHOLIGHT, TEVA), lecture fees when speaking at the invitation of sponsor (IBSA-GENEVRIER, MYLAN, CNIEL, DAIRY RESEARCH COUNCIL (DRC), TEVA), grant Support from Industry (All through Institution) (IBSA-GENEVRIER, MYLAN, CNIEL, RADIUS HEALTH). He also a shareholder of SARQOL SRL, a spin-off of the University of Liege as well as the CARES SRL, former spin-off of the University of Liège. AJ Cruz-Jentoft reports consulting fees or paid advisory boards from REJUVENATE BIOMED, RENEO PHARMACEUTICASL and AKROS PHARMA on the development of drugs to treat sarcopenia. Other authors reported no conflicts of interest in relation to this work.